TScan Therapeutics, Inc.

NASDAQ:TCRX

Biotechnology

Healthcare
$0.82 +2.23%

+$0.02 today

Market cap
$50.37M
Beta
1.03
P/E (TTM)
-1.0
EPS (TTM)
-$0.96
52W Low $0.85High $2.57

Volume 0.00M

Average 0.81M

TCRX Pre-Tax Margin

Income before tax as a percentage of revenue.

TScan Therapeutics, Inc.NASDAQ: TCRX

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -2919.1%

Pre-tax margin was -2919.1% in Q1 FY2026, down 1347.2 pp from a year earlier. On a trailing-twelve-month basis it was -1360.6%, up 1613.5 pp year over year. Over 3 fiscal years it narrowed by 767.6 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-2919.1%-2024.1 pp QoQ
Last fiscal yearDec 2025
-1256.8%+3270.8 pp YoY
LTMMar 2026
-1360.6%+1613.5 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1347.2 pp——
1 year+3270.8 pp——
3 years-767.6 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1256.8%
Year-over-year change
+3270.8pp

Pre-Tax Margin vs competitors

How TCRX compares with its peers on the latest reported figures

  • TCRX's LTM Mar 2026 pre-tax margin of -1360.6% is the lowest of the 4 companies compared; the peer median is 14.7%.
  • Its year-over-year change of +1613.5 pp is the highest of 4, against a peer median of +136.7 pp.
  • Over three fiscal years its change of -767.6 pp compares with a peer median of +228.8 pp.
TCRX Competitors Peer median
Pre-Tax Margin for TCRX and competitors
Company Period LTM level YoY 3-year change
FBIOFortress Biotech, Inc.LTM Mar 2026201.4% +385.1 pp+228.8 pp
VXRTVaxart, Inc.LTM Mar 202614.7% +136.7 pp+100652.9 pp
NTRBNutriband Inc.LTM Apr 2026-448.4% -32.6 pp-188.5 pp
TCRXTScan Therapeutics, Inc.LTM Mar 2026-1360.6% +1613.5 pp-767.6 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
XBITXBiotech Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding TCRX) 14.7%+136.7 pp+228.8 pp

Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.14M13.54M21.05M2.82M10.33M
Cost of Revenue00002.87M
Gross Profit10.14M13.54M21.05M2.82M7.46M
Gross Margin100.0%100.0%100.0%100.0%72.2%
Research & Development44.95M59.82M88.15M107.35M114.15M
Selling, General & Admin13.83M20.35M25.49M29.56M31.99M
Operating Expenses58.78M80.17M114.51M137.64M143.27M
Depreciation & Amortization3.33M5.14M5.36M4.11M2.87M
EBITDA(45.3M)(59.91M)(80.1M)(119.74M)(124.13M)
EBITDA Margin-446.7%-442.6%-380.5%-4252.1%-1202.2%
Operating Income(48.64M)(66.64M)(93.46M)(134.82M)(135.81M)
Operating Margin-479.6%-492.3%-444.0%-4787.7%-1315.4%
Interest Income16K1.59M8M12.07M8.82M
Interest Expense01.18M3.76M3.65M2.77M
Other Income / Expenses16K415K4.24M7.32M6.05M
Income Before Tax(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Pre-Tax Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
Income Tax Expense00000
Net Income(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Net Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
EPS (Basic)(2.03)(2.74)(1.36)(1.14)(1.00)
EPS (Diluted)(2.03)(2.74)(1.36)(1.14)(1.00)
Weighted Avg Shares23.91M24.05M65.6M111.99M129.86M
Weighted Avg Shares (Diluted)23.91M24.05M65.6M111.99M129.86M

TScan Therapeutics, Inc.

NASDAQ:TCRX

Intrinsic Alpha fair value

Locked

Current Price

$0.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.